Context. “Compound 23” (LEO Pharma) is an oral IL-17A protein−protein interaction modulator being developed for psoriasis and other inflammatory diseases. Like most cytokines, the involvement of IL-17A in chronic…
Context. “Compound 23” (LEO Pharma) is an oral IL-17A protein−protein interaction modulator being developed for psoriasis and other inflammatory diseases. Like most cytokines, the involvement of IL-17A in chronic…